STADA Arzneimittel — Investor Presentation (March 2018)
12 slides from STADA Arzneimittel's investor presentation, Mar 8, 2018
Slide 1: STADA: New Skills – Pressekonferenz Frankfurt
PK Frankfurt STADA: New Skills Pressekonferenz Frankfurt Sofitel 08. März 2018 On Eagles’ Wings 08.03.2018 STADA's journey
Slide 2: New Skills
Where do we want to be in 5 years? New skills Today we are not a true global player Today we have few “high entry barrier” products On Eagles’ Wings NEW SKILLS 08.03.2018 STADA's journey
Slide 3: External and Internal Factors
Where do we want to be in 5 years? External and Internal Factors High Execution speed New markets, Portfolio Differentiation new channels Process re-engineering and Cost Leadership Corporate Culture Regular Regular Importance High On Eagles’ Wings 08.03.2018 STADA's journey
Slide 4: Prescription and Non-Prescription Business
Where do we want to be in 5 years? STADA will be present in prescription and non-prescription remedies Prescription Business Non Prescription Business Specialties with Prescription OTC, Probiotics, innovative Generics Cosmeceuticals, Food features: incompatibility, Diagnostics Unbranded and Mostly b
Slide 5: STADA will grow faster than the market
Where do we want to be in 5 years? STADA will grow faster than the market Sales ranking 2023 CAGR 2018-2023 Teva Sandoz Mylan P4 STADA A strong European Nr. 3 , globally Top 5 On Eagles’ outperforming the markets Wings 08.03.2018 STADA's journey
Slide 6: Generics and specialized Therapeutic Clusters
Where do we want to be in 5 years? STADA will be present in Generics and in specialized Therapeutic Clusters CNS / Pain / Abuse Diabetes CNS complications Adipositas Opioids Lipo- Metabolic Diabetes metabolism Syndrom Non Opioids (Pain) Hyper- Abuse Therapies tension Oncology Ophthalmology Support C
Slide 7: Clearly positioned Consumer Health business
Where do we want to be in 5 years? STADA will have a clearly positioned Consumer Health business We have a number of pan-European (umbrella) brands We pursue bolt on acquisitions We have a strong CH EU5/UK/ CIS business Food incompatibility, Enzymes and Diagnostics From Probiotics to Metabiotics Int
Slide 8: Growth underpinned by investment in R&D
Where do we want to be in 5 years? Our growth will be underpinned by investment in R&D Total spend on R&D * as a % of Group sales 8 6 Includes over €100m planned spending on Biosimilars in 2018-2020 (co-development and in-licensing) 2016 2016-2017 2017 2018-2020 average planned * Sum of expensed + c
Slide 9: Acquisitions and Greenfield: Developed and Emerging Markets
Where do we want to be in 5 years? Acquisitions and Greenfield Developed Markets Emerging Markets On Eagles’ Wings 08.03.2018 STADA's journey
Slide 10: Main initiatives by region
Where do we want to be in 5 years? Main initiatives All of Europe: build Hospital presence and prepare launch of Biosimilars with collateral chemical portfolio Germany: Defend our top tender position and successfully manage Consumer care products. Launch Specialty portfolio in STADApharm UK: growth
Slide 11: Efficiency gains in processes
Where do we want to be in 5 years? Efficiency gains in processes • Group wide portfolio standards I2M • Time to Market • Selected in-house technology platforms R&D • Strategic IP projects / more active • Capacity de-bottlenecking / In-house transfers Manufacturing • Growth supporting manufacturing n
Slide 12: Main Initiatives Summary
Main Initiatives Summary • Higher investments in more complex products Biosimilars, Generics with „hard to make“ delivery systems, OTC) • New Channels: Build Hospital and Digital presence • New Geographies focussing on Emerging Markets • Process re-engineering with saving potential On Eagles’ Wings
STADA Arzneimittel — Investor Presentation (March 2018) on 6ix